Randomized phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms RESORT
- 30 Jan 2024 Status changed from active, no longer recruiting to completed.
- 10 Dec 2013 Pharmacogenomic analysis of follicular lymphoma patients presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 10 Dec 2012 Patient-reported outcomes and QOL data (n=253) presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.